Carbon monoxide (CO), a gaseous mediator produced by haem oxygenases (HOs), has been shown to prevent stress-, ethanol-, aspirin-and alendronate-induced gastric damage; however, its role in gastric ulcer healing has not been fully elucidated. We investigated whether CO released from tricarbonyldichlororuthenium (II) dimer (CORM-2) can affect gastric ulcer healing and determined the mechanisms involved in this healing action.
Introduction
Carbon monoxide (CO) has been identified as an endogenous gaseous mediator produced from haem along with biliverdin and ferrous iron (Fe 2+ ) via a reaction catalysed by haem oxygenase (HO) enzymes (Ryter and Otterbein, 2004; Ryter et al., 2006) . Three isoforms of HO have been described, but only HO1 and HO2, which are encoded by different genes, exert biological activity (Maines et al., 1986) . HO1 expression may be induced by a wide range of stressful stimuli including oxidative stress and proinflammatory cytokines (Ryter and Otterbein, 2004; Ryter et al., 2006) , whereas HO2 is a constitutive isoform of the enzyme (Maines, 1988) . CO has been reported to regulate many physiological functions in the body and is involved in the normal physiology of the gastrointestinal tract (Motterlini et al., 2002; Farrugia and Szurszewski, 2014; Magierowski et al., 2015) . Moreover, CO has been shown to exert anti-oxidative, anti-inflammatory and anti-apoptotic activity (Otterbein et al., 2000; Silva et al., 2006) and has been implicated in the regulation of duodenal HCO 3 À ion secretion (Takasuka et al., 2011; Takeuchi et al., 2012) and the modulation of bile secretion (Chen et al., 2013) . CO, along with hydrogen sulfide (H 2 S) and NO, is considered to be a physiologically active gaseous mediator that has an essential role in the gastric mucosal defence system Gemici and Wallace, 2015) . Interestingly, CO produced endogenously or released from its pharmacological donors, including tricarbonyldichlororuthenium (II) dimer (CORM-2), has been demonstrated to protect the gastric mucosa against the damage induced by exposure to systemic stress or the administration of ethanol, alendronate or aspirin (ASA) (Gomes et al., 2010; Magierowska et al., 2015 Magierowska et al., , 2016 Magierowski et al., 2016a,b; Kwiecien et al., 2016) . Interestingly, COsaturated saline promotes gastric ulcer healing, but the mechanism of this beneficial effect on ulcer healing has been little studied (Takagi et al., 2016) . In particular, the involvement of CO-releasing CORM-2 in the healing of preexisting gastric ulcers has not been investigated so far. Additionally, the mechanisms involved in CO-mediated gastric ulcer healing have not been fully explained.
The aim of our study was to determine for the first time, if the treatment with CO-releasing CORM-2, HO1 inducing haemin or HO inhibiting zinc protoporphyrin IX (ZnPP), could affect the healing of experimental acetic acid (AA)-induced gastric ulcers and the accompanying changes in the gastric blood flow (GBF) at the ulcer margin, a crucial region for ulcer healing. Additionally, we attempted to investigate the underlying molecular mechanisms involved in the beneficial activity of CO at the ulcer margin, with special emphasis being placed on determining the mRNA and protein expression of EGF, the EGF receptor (EGFR) and its phosphorylation. Another attempt was made to determine whether CO alters the gastric mucosal expression of angiogenic VEGFA, HO1, HO2, nuclear factor (erythroidderived 2)-like 2 (Nrf2), hypoxia-inducible factor-1α (HIF-1α) and pro-inflammatory factors IL-1β, TNF-α, iNOS and COX-2. We also aimed to shed light on the possible role of the soluble GC (sGC)/cGMP system, NO biosynthesis, endogenous PG production by COX and ATP-sensitive potassium (K ATP ) channel (also known as K ir 6.1 channel ) activity in CO-mediated acceleration of ulcer healing.
Methods

Animals, experimental design, chemicals and drugs treatment
Eighty-five 8-to 9-week-old male Wistar rats with an average weight of 220-300 g were used in this study. All procedures were approved by the Institutional Animal Care and Use Committee of Jagiellonian University Medical College in Cracow and were in accordance with Helsinki Declaration and with implications for replacement, refinement or reduction (the 3Rs) principle (Decision No.: 22/2016; date: 20 July 2016) . Animals were purchased from Centrum Medycyny Doswiadczalnej, Medical University of Silesia (Katowice, Poland). All rats were fed standard food and water ad libitum and were kept at a temperature of 20 ± 2°C, humidity 50-60% and on a 12 h light/dark cycle. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Experimental chronic gastric ulcers were induced by the serosal application of concentrated (100%) acetic acid, according to the rat-based model originally described by Okabe et al., 1971 and used by our group with some modifications, as reported previously (Szlachcic et al., 2013) . Animals were fasted for 24 h with free access to tap water before surgery. Briefly, at day 0, under isoflurane anaesthesia, acetic acid in a volume of 40 μL was applied to the serosal part of the stomach for 25 s to induce a gastric lesion on the border of oxyntic and antral mucosa. This lesion developed into a chronic ulcer, which affected the whole gastric mucosa and submucosa, penetrating to the muscularis mucosae. The healing of this ulcer is morphologically similar to that observed clinically in patients who suffering from peptic ulcer disease (Halter et al., 1995; Okabe and Amagase, 2005) .
One day after the induction of a gastric ulcer, animals were randomly divided into appropriate experimental groups consisting of five animals in each (n = 5) and were treated daily, intragastrically (i.g.), throughout the period of 9 days with (i) vehicle (saline or DMSO/saline solution 1/10); (ii) CORM-2 (0.1-10 mg·kg À1 ); (iii) RuCl 3 (2.5 mg·kg À1 ), as a negative control for CORM-2, which does not release CO (Takasuka et al., 2011; Magierowska et al., 2015) ; (iv) haemin, an HO1 inducer (Park et al., 2013; Magierowska et al., 2016) , at a dose of 5 mg·kg À1 , which has been previously reported to protect the gastric mucosa against ethanol-induced damage ; and (v) ZnPP, an HOs inhibitor (Hirai et al., 2007) , at a dose of 10 mg·kg À1 , previously reported to decrease CO content in gastric mucosa . In the majority of experiments, CORM-2 was administered at a dose of 2.5 mg·kg À1 , which decreased the ulcer area by more than 50% compared with the vehicle control group. The dose of RuCl 3 administered i.g., 2.5 mg·kg À1 , which was equal to the effective dose of CORM-2. In order to determine the mechanism of the healing effect of CO on the ulcer, CORM-2 (2.5 mg·kg À1 ) was further administered throughout the 9 days, either alone or in combination with (i) 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 5 mg·kg À1 i.g.), a sGC inhibitor (Cechova and Pajewski, 2004; Brancaleone et al., 2008) 
, a NOS inhibitor (Griffith and Kilbourn, 1996) ; (iii) indomethacin (5 mg·kg À1 i.g.), the non-selective COX inhibitor (Magierowski et al., 2017b) ; or (iv) glibenclamide (10 mg·kg À1 i.g.), the K ATP s inhibitor (Silva et al., 2014) . The doses of ODQ, L-NNA, indomethacin and glibenclamide were selected based on previously published data (Silva et al., 2014; Magierowska et al., 2015; Magierowski et al., 2016a; 2017a) . CORM-2, ZnPP, ODQ or haemin were dissolved in DMSO and saline (1:10) (Magierowski et al., 2016a) , while other chemicals and drugs were dissolved in saline. All of the abovementioned chemicals were provided by Sigma-Aldrich (Schnelldorf, Germany).
Measurement of GBF, gross and microscopic assessment of gastric ulcer healing
After 9 days of treatment, the rats with gastric ulcers were anaesthetized using pentobarbital (60 mg·kg À1 i.p.), and the stomachs were opened along the greater curvature for the GBF measurement at ulcer margin by a laser Doppler flowmeter (Laserflo blood perfusion monitor, model BPM 403A; Vasamedics, St Paul, MN, USA), as described elsewhere (Magierowski et al., 2017a) . Briefly, the GBF was determined at the ulcer margin and healthy (intact) nonulcerated gastric mucosa by a person who did not know in which experimental group the animals belonged to. Average values of three measurements in each animal were expressed as mL·min À1. 100 g À1 of gastric mucosa. Animals were then killed by the application of a high dose of pentobarbital.
The gastric mucosa was photographed as described previously (Majka et al., 2010; Magierowski et al., 2016a) . Next, the stomach was excised, and the area of gastric ulcer in each stomach was determined blindly using computerized planimetry (Morphomat; Carl Zeiss, Berlin, Germany) 2017b) .
For histology, gastric tissue sections excised from ulcer margin were fixed in 10% buffered formalin, pH 7.4. Samples were dehydrated by passing them through a series of alcohols with incremental concentrations, equilibrated in xylene for 10-15 min and embedded in paraffin; paraffin blocks were cut into about 4 μm sections using a microtome. The prepared specimens were stained with haematoxylin and eosin and evaluated using a light microscope (Eclipse TS100; Nikon, Amsterdam, The Netherlands) (Majka et al., 2010; Magierowski et al., 2016a) .
The gastric mucosal samples from the ulcer margin were scraped off on ice, snap-frozen in liquid nitrogen and stored at À80°C until further analysis Magierowski et al., 2016a) .
Determination of mRNA expression for EGF, HO1, HO2, COX-2, iNOS, HIF-1α, TNF-α, IL-1β and β-actin in gastric mucosa by real-time PCR
The expression of mRNA for EGF, HO1, HO2, COX-2, iNOS, HIF-1α, TNF-α, IL-1β and β-actin (as housekeeping gene) in gastric mucosa was determined by semiquantitative real-time PCR, as described previously . Briefly, RNA was isolated from gastric mucosal samples using GeneMATRIX Universal RNA Purification Kit (EURx, Gdansk, Poland). A highcapacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Cambridge, MA, USA) was used to perform reversed transcription to cDNA. The expression of HO1, HO2, COX-2, iNOS, HIF-1α, TNF-α and IL-1β was determined using specific primers, as described elsewhere (Magierowski et al., 2016a,b) . To determine EGF mRNA expression, 5 0 -CTACTACAGGACTCGGAAGCAG-3 0 forward and 5 0 -GTTGGGGACCAGAAGACACC-3 0 reverse primers were used. β-actin expression as reference gene was determined using 5 0 -CTAAGGCCAACCGTGAAAAGA-3 0 forward and 5 0 -TGGTACGACCAGAGGCATAC-3 0 reverse primers. The expression of all genes of interest was determined in triplicate using SG qPCR Master Mix (2×) with SYBRGreen (EURx) and thermal cycler Quant Studio 12K Flex (Thermo Fisher Scientific). Results were analysed using the 2 ÀΔCT method and expressed as relative expression (Schmittgen and Livak, 2008) .
Gastric mucosal protein expression of HO1, Nrf2, iNOS, COX-2, VEGFA, EGFR, phospho-EGFR (Tyr 845 ) and β-actin proteins analysed by Western blot Protein expressions for HO1, Nrf2, iNOS, COX-2, VEGFA, EGFR, phospho-EGFR (Tyr 845 ) and β-actin in gastric mucosa were determined using Western blots, as described in our previous studies Magierowski et al., 2016a,b) . Rabbit monoclonal anti-HO1 (ab68477; Abcam, Cambridge, UK) at a dilution of 1:2000, rabbit polyclonal anti-Nrf2 (16396-AP-1; Proteintech, Manchester, UK) at a dilution of 1:500, rabbit polyclonal antiiNOS (ab3523; Abcam) at a dilution of 1:400, rabbit polyclonal anti-COX-2 (ab15191; Abcam) at a dilution of 1:500, rabbit polyclonal anti-VEGFA (ab46154; Abcam) at a dilution of 1:1000, rabbit polyclonal anti-EGFR (2646S; Cell Signaling Technology, Danvers, MA, USA) at a dilution of 1:1000, rabbit polyclonal anti-phospho-EGFR (Tyr845) (2231S; Cell Signaling Technology) at a dilution of 1:1000 and mouse monoclonal anti-β-actin (3700S; Cell Signaling Technology) at a dilution of 1:1000 were used as primary antibodies. Protein expression was visualized using HRP-linked secondary goat anti-rabbit IgG H&L antibody (ab97051; Abcam) at a dilution of 1:2000 or antimouse IgG antibody (7076P2; Cell Signaling Technology) at a dilution of 1:2000 where appropriate. Anti-Nrf2, anti-iNOS, anti-EGFR and anti-phospho-EGFR antibodies were diluted in 5% BSA, and all other primary and secondary antibodies were diluted in 5% non-fat milk. Chemiluminescence was developed using WesternSure® ECL Substrate (LI-COR, Lincoln, NE, USA) or WesternBright Quantum (Advansta, Menlo Park, CA, USA) and was measured using a C-DiGit® Blot Scanner (LI-COR). The intensity of bands was determined and analysed using Image Studio 4.0 software (LI-COR). The expression of each protein of interest was determined using five samples per experimental group, and the values obtained were normalized to the BJP M Magierowski et al.
expression of β-actin as a loading control (Magierowski et al., 2016a) .
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Experiments and data collection were done by operators blinded to the sample identity. Results were analysed using GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). Results are presented as mean ± SEM. Statistical analysis was conducted using Student's t-test or ANOVA with Dunnett's multiple comparison or Tukey's post hoc test if more than two experimental groups were compared, run only if F achieved P < 0.05 and there was no significant variance inhomogeneity. The size for each experimental group was of n = 5. P < 0.05 was considered to be statistically significant.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
The effect of CO releasing CORM-2 on the area of gastric ulcer and the GBF at the ulcer margin Figure 1 shows changes in ulcer area (A) and the GBF at the ulcer margin (B) examined at day 9 after ulcer induction. CORM-2 administered at a dose of 0.1 mg·kg À1 or 1 mg·kg À1 ·day À1 i.g. failed to affect the area of gastric ulcer and GBF at ulcer margin as compared with vehicle control rats ( Figure 1A , B). However, treatment with CORM-2 at a dose of 2.5 mg·kg À1 ·day À1 i.g. significantly decreased ulcer area and significantly increased GBF at ulcer margin as compared with those observed in the group treated with vehicle ( Figure 1A , B, respectively). No further reduction in area of gastric ulcer and increase in GBF at ulcer margin were recorded in groups treated with CORM-2 10 mg·kg À1 as compared with animals treated with CORM-2 2.5 mg·kg
À1
( Figure 1A, B) .
Comparison of the effect of daily treatment with CORM-2, haemin, ZnPP and RuCl 3 on changes in ulcer size, GBF at ulcer margin and microscopic and macroscopic appearance of gastric mucosa Figure 2 shows the alterations in the area of gastric ulcer (A) and GBF at ulcer margin (B) assessed at day 9 after ulcer induction in rats treated daily with vehicle, CORM-2 (2.5 mg·kg
CORM-2 and haemin significantly decreased mean ulcer area and significantly increased GBF at ulcer margin as compared with the group treated with vehicle ( Figure 2A, B) . In contrast, treatment with ZnPP and RuCl 3 significantly increased the ulcer area and had no effect on GBF as compared with the group treated with vehicle ( Figure 2A, B) . Figure 2C shows representative microscopic and macroscopic appearance of gastric ulcer in rats analysed at day 9 following its induction in groups treated daily with vehicle, CORM-2 (2.5 mg·kg
ZnPP (10 mg·kg À1 i.g.) or RuCl 3 (2.5 mg·kg À1 i.g.). Treatment with CORM-2 or haemin reduced the gastric ulcer depth and size causing partial re-epithelialization of ulcer niche as compared with vehicle control group in which Figure 1 The effect of CORM-2 on ulcer size and GBF at the ulcer margin. (A) Gastric ulcer area in rats after 9 days of i.g. treatment with vehicle or CORM-2 (0.1-10 mg·kg À1 ·day À1 ). (B) GBF at the ulcer margin. Results are expressed as mean ± SEM for n = 5 rats per experimental group. Asterisk (*) indicates significant change as compared with vehicle control group (P < 0.05).
Figure 2
The effect of daily treatment with CORM-2, haemin, ZnPP and RuCl 3 on changes in ulcer area and GBF at the ulcer margin. (A) Mean area of gastric ulcer in rats after 9 days of daily i.g. treatment with vehicle, CORM-2 (2.5 mg·kg À1 ), haemin (5 mg·kg À1 ), ZnPP (10 mg·kg À1 ) or RuCl 3 (2.5 mg·kg À1 ). (B) GBF at the ulcer margin. Results are expressed as mean ± SEM for n = 5 rats per experimental group. Asterisk (*) or cross ( + )
indicates significant change as compared with vehicle control group (P < 0.05). (C) Microscopic and macroscopic appearance of representative gastric mucosa with gastric ulcer. Images were collected from gastric mucosa of rats 9 days after the induction of a gastric ulcer by administration of acetic acid followed by the daily treatment with vehicle, CORM-2 (2.5 mg·kg The effect of concurrent treatment of CORM-2 with indomethacin, L-NNA, ODQ or glibenclamide on alterations in ulcer area and GBF at ulcer margin Figure 3 shows the changes in area of gastric ulcer (A) and GBF at ulcer margin (B) 9 days after ulcer induction in rats treated daily with vehicle or CORM-2 (2.5 mg·kg À1 i.g.)
administered alone or in combination with indomethacin (5 mg·kg
or glibenclamide (10 mg·kg À1 i.g.). When indomethacin or ODQ was co-administered with CORM-2, the ulcer area was significantly increased, and a decrease in GBF at ulcer margin was observed as compared with the group treated with CORM-2 alone ( Figure 3A , B, respectively). The cotreatment of CORM-2 with L-NNA or glibenclamide significantly increased the ulcer area and significantly decreased the GBF at ulcer margin as compared with the group treated with CORM-2 alone ( Figure 3A, B) . The combined administration of CORM-2 with L-NNA or glibenclamide significantly decreased the ulcer area as compared with the vehicle-treated animals ( Figure 3A ). These alterations in ulcer area and GBF at ulcer margin induced by the combined treatment of CORM-2 with indomethacin, L-NNA, ODQ or glibenclamide indicate the involvement of PG/ COX system, NO biosynthesis, sCG/cGMP and K ATP activity, respectively, in the CO-mediated ulcer healing.
Gastric mucosal expression of HO1, HO2 and Nrf2 at ulcer margin 9 days after gastric ulcer induction Figure 4A -D shows the alterations in HO1, HO2 mRNA expression and HO1 and Nrf2 protein expression in healthy gastric mucosa and on the margin of the acetic acid-induced ulcers. HO1 mRNA and Nrf2 protein expression was significantly increased at ulcer margin as compared with healthy gastric mucosa ( Figure 4A, D) . Daily treatment with CORM-2 significantly decreased HO1 mRNA and protein expression as compared with vehicle control group ( Figure 4A , C). CORM-2 or haemin (5 mg·kg À1 i.g.) significantly decreased Nrf2 protein expression in gastric mucosa as compared with vehicle-treated rats ( Figure 4D ). As shown in Figure 4A , C, the expression of mRNA and protein for HO1 was not significantly affected by treatment with ZnPP as compared with vehicle control animals. In contrast, HO2 mRNA expression at the ulcer margin was significantly decreased in the group treated with ZnPP (10 mg·kg À1 i.g.) as compared with rats treated with vehicle ( Figure 4B ). These results indicate that the HO/Nrf2 pathway is involved in CO-mediated ulcer healing. Carbon monoxide accelerates gastric ulcer healing BJP EGF, EGFR, phospho-EGFR and VEGFA mRNA or protein expression in healthy gastric mucosa and at ulcer margin Figure 5A -F shows gastric mucosal mRNA expression for EGF and protein expression for phospho-EGFR, EGFR, phospho-EGFR to EGFR expression ratio and VEGFA in healthy gastric mucosa or at ulcer margin in rats, which had been treated daily with vehicle or CORM-2 (2.5 mg·kg À1 i.g.). The expression of mRNA for EGF was significantly increased at the ulcer margin in the group treated with CORM-2 as compared with
Figure 4
Alterations in HO1, HO2 mRNA and HO1 and Nrf2 protein expression in healthy gastric mucosa and at the ulcer margin. (A) Expression of mRNA for HO1 in healthy gastric mucosa (intact) and at the gastric ulcer margin [acetic acid (AA) induced ulcer] observed after 9 days of i.g. treatment with vehicle, CORM-2 (2.5 mg·kg À1 ) or ZnPP (10 mg·kg À1 ). (B) Expression of mRNA for HO2 in healthy gastric mucosa (intact) and at the gastric ulcer margin observed after 9 days of i.g. treatment with vehicle, CORM-2 or ZnPP. (C) Protein expression and representative bands for HO1 and β-actin proteins (lower panel) in healthy gastric mucosa (intact) and at gastric ulcer margin (AA ulcer) after 9 days of i.g. treatment with vehicle, CORM-2, dose of haemin or ZnPP. (D) Protein expression and representative bands for Nrf2 and β-actin proteins (lower panel) in healthy gastric mucosa (intact) and at gastric ulcer margin (AA ulcer) 9 days of i.g. treatment with vehicle, CORM-2, haemin or ZnPP. Results are expressed as mean ± SEM for n = 5 samples per experimental group. Asterisk (*) indicates significant change as compared with healthy gastric mucosa (intact) (P < 0.05). Significant change as compared with the vehicle-treated animals is indicated by a cross ( + ) (P < 0.05).
animals treated with vehicle ( Figure 5A ). EGFR and phospho-EGFR protein expression was significantly increased at the ulcer margin as compared with healthy gastric mucosa (Figure 5 B, C, F). Daily treatment with CORM-2 significantly decreased the expression of proteins for phospho-EGFR, EGFR and the ratio of phospho-EGFR and EGFR at the ulcer margin Expression of mRNA for EGF and protein expression of EGFR, phospho-EGFR and VEGFA in healthy gastric mucosa and at the ulcer margin. (A) Expression of mRNA for EGF in healthy gastric mucosa (intact) or at the ulcer margin [acetic acid (AA) induced ulcer] in rats treated daily with vehicle or CORM-2 for 9 days. (B) Protein expression for EGFR in healthy gastric mucosa (intact) and at gastric ulcer margin (AA ulcer) after 9 days of i.g. treatment with vehicle or CORM-2 (2.5 mg·kg À1 ·day À1 ). (C) Protein expression for phospho-EGFR in healthy gastric mucosa (intact) and at gastric ulcer margin (AA ulcer) after 9 days of i.g. treatment with vehicle or CORM-2 (2.5 mg·kg À1 ·day À1 ). (D) The ratio of phospho-EGFR/EGFR protein expression in rats with AA ulcer treated i.g. for 9 days with vehicle or CORM-2. (E) Protein expression for VEGFA in healthy gastric mucosa (intact) and at gastric ulcer margin (AA ulcer) after 9 days of i.g. treatment with vehicle or CORM-2. (F) Representative bands of protein expression for EGFR, phospho-EGFR, VEGFA and respective β-actin in healthy gastric mucosa (intact) and at gastric ulcer margin (AA ulcer) after 9 days of i.g. treatment with vehicle or CORM-2. Results are expressed as mean ± SEM for n = 5 samples per experimental group. Asterisk (*) indicates significant change as compared with healthy gastric mucosa (intact) (P < 0.05). Significant change as compared with the vehicle-treated animals is indicated by a cross ( + ) (P < 0.05).
as compared with rats treated with vehicle ( Figure 5B, C, D, F) . Protein expression of VEGFA was significantly increased at the ulcer margin as compared with healthy gastric mucosa, and this effect was not significantly affected by treatment with CORM-2 ( Figure 5E , F). These findings indicate that the possible modulation by CORM-2 of the expression of these angiogenic and growth-promoting factors is involved in its mechanism of gastric ulcer healing.
Expression of mRNA and proteins for pro-inflammatory iNOS and COX-2 in healthy gastric mucosa and at gastric ulcer margin Figure 6A -D shows the alterations in the mRNA and protein expression of iNOS and COX-2 and representative bands of protein expressions for β-actin, iNOS and COX-2 (lower panels of Figure 6C , D) in healthy and ulcerated gastric mucosa, determined at day 9 after ulcer induction, in rats treated with vehicle or CORM-2 (2.5 mg·kg À1 i.g.). Protein and mRNA expression of iNOS was significantly increased at the ulcer margin as compared with healthy gastric mucosa ( Figure 6A , C). In contrast, daily treatment with CORM-2 significantly decreased iNOS mRNA and protein expression at the ulcer margin as compared with rats treated with vehicle ( Figure 6A , C). The expression of mRNA for COX-2 was significantly increased at the ulcer margin as compared with those obtained in healthy gastric mucosa ( Figure 6B ). Daily treatment with CORM-2 significantly decreased COX-2 mRNA and protein expression at the ulcer margin as compared with those recorded in rats treated with vehicle ( Figure 6B, D) . These findings indicate that the antiinflammatory action of CORM-2 is induced by its ability to inhibit the expression of pro-inflammatory markers iNOS and COX-2.
Expression of mRNA for pro-inflammatory cytokines IL-1β, TNF-α and anti-hypoxic HIF-1α in healthy gastric mucosa and at gastric ulcer margin Figure 7A -C shows the mRNA expression of IL-1β, TNF-α and HIF-1α in healthy gastric mucosa and at the ulcer margin after 9 days of treatment with vehicle or CORM-2 (2.5 mg·kg À1 i.g.).
The expression of mRNA for IL-1β, TNF-α and HIF-1α was significantly increased at the ulcer margin as compared with healthy gastric mucosa ( Figure 7A -C). Daily treatment with CORM-2 significantly decreased IL-1β, TNF-α and HIF-1α mRNA expression at ulcer margin as compared with rats treated with vehicle ( Figure 7A-C) . The changes in expression of these markers reflect the potent anti-inflammatory and anti-hypoxic activity of CORM-2.
Discussion
Our study revealed that daily treatment with the COreleasing CORM-2 (0.1-10 mg·kg À1 i.g.) dose-dependently accelerated the healing of pre-existing gastric ulcers, and this effect was accompanied by an increase in GBF at the ulcer margin. We observed that CORM-2 exerts a potent ulcerhealing effect when administered daily, i.g., at a dose of 2.5 mg·kg À1 for 9 days after the induction of an ulcer. In contrast, treatment with RuCl 3 , which does not release CO and was considered as a negative control to CORM-2, even delayed gastric ulcer healing and failed to affect GBF. Interestingly, haemin, which is a known inducer of HOs, enzymes involved in the production of endogenous CO, accelerated gastric ulcer healing and raised GBF, having similar effects to those exhibited by CORM-2. Moreover, inhibition of HOs by treatment with ZnPP evidently delayed gastric ulcer healing, as confirmed by an increase in ulcer area and fall in GBF at the ulcer margin as compared with the vehicle-treated group. We have recently reported that the administration of CORM-2 at doses of 1, 5 and 50 mg·kg À1 increased CO content in gastric mucosa . Pretreatment with CORM-2 dose-dependently reduced the formation of gastric lesions induced by stress, and this protective effect was accompanied by an increase in GBF . Furthermore, CORM-2 was effective in protecting the gastric mucosa against damage induced by ulcerogenes such as ethanol, alendronate and aspirin Magierowski et al., 2016a,b; 2017a) . Interestingly, haemin dose-dependently reduced stress-or ethanol-induced gastric damage formation, while ZnPP exerted opposite effects . These observations indicate that CO produced endogenously by the activity of HO1 or that released from its pharmacological donors after i.g. administration plays an important role in the mechanism of gastric mucosal defence and gastroprotection, but whether this gaseous molecule can affect ulcer healing remains unknown. Herein, we have demonstrated that CO-releasing CORM-2 enhances the GBF and accelerates the healing of pre-existing gastric ulcers. These observations suggest a possible therapeutic application of CORM-2 and other CO-releasing chemicals and the potential usefulness of future drugs containing CO-releasing moieties in the treatment of gastric ulcers. We observed that co-treatment of the sGC inhibitor, ODQ, or non-selective COX inhibitor, indomethacin, with CORM-2 reversed the beneficial effect of this CO donor on gastric ulcer healing suggesting that CO acts via cGMP and PG-mediated pathways. Similarly, CORM-2-mediated gastroprotection against aspirin-or ethanol-induced injury was reduced by co-treatment with ODQ or indomethacin respectively (Gomes et al., 2010; Magierowska et al., 2015; Magierowski et al., 2016a) . Bucci et al. (2012) and Zhou et al. (2016) also demonstrated that H 2 S can stimulate NOmediated sGC activity, and therefore, H 2 S-mediated vasorelaxation has been considered to be cGMP-dependent, similar to the effect of CO. Moreover, H 2 S released from diallyl sulfide decreased nitrite production in intestinal epithelial cells (Fasolino et al., 2015) . Our group reported that CO released from CORM-2 decreased NO content in gastric mucosa compromised by stress . These findings suggest that three gaseous molecules CO, H 2 S and CO interact with each other in the mechanism of vasorelaxation and gastroprotection and that CO, similar to H 2 S, can interact with NO exerting a beneficial protective action in gastric mucosa, at least in part, via activation of the cGMP/sGC pathway (Cacanyiova et al., 2016) . Therefore, we assume that the hyperaemic and ulcer-healing effects of CO observed in our study may depend on the activation of NO/cGMP and on the biosynthesis of endogenous PGs. Indeed, co-treatment of CORM-2 with L-NNA, a non-selective NOS inhibitor, reduced the rate of ulcer healing and increase in GBF evoked by this CO donor. This observation is in line with previously published evidence showing that the inhibition of NOS reduced the gastroprotective effect of CORM-2 against aspirin-induced injury (Magierowski et al., 2017a) . Moreover, the peripheral antinociceptive effect of the HO/CO pathway and possibly its contribution to gastroprotection could be mediated by the activation of K ATP channels (Pereira de Ávila et al., 2014) . We found that glibenclamide reduced the ulcer-healing effect of CORM-2 suggesting that the beneficial effect of CO on gastric mucosal repair and regeneration as well as its role in regulation of gastric for iNOS and β-actin in healthy gastric mucosa (intact) and at the gastric ulcer margin (AA ulcer) after 9 days of i.g. treatment with vehicle or CORM-2. (D) Expression of COX-2 protein and representative bands of protein expression for COX-2 and β-actin in healthy gastric mucosa (intact) and at the gastric ulcer margin (AA ulcer) after 9 days of i.g. treatment with vehicle or CORM-2. Results are expressed as mean ± SEM for n = 5 samples per experimental group. Asterisk (*) indicates significant change as compared with healthy gastric mucosa (intact) (P < 0.05). Significant change as compared with the vehicle-treated animals is indicated by a cross ( + ) (P < 0.05).
microcirculation in the ulcer area involves the collaboration of the endogenous NO/sGC system, the activity of the K ATP channel and biosynthesis of endogenous PGs.
Previously it was shown that HO1 expression at the ulcer margin is sequentially and time-dependently increased during course of ulcer healing (Guo et al., 2003) . We confirmed that HO1 mRNA expression was elevated at the ulcer margin in vehicle (control)-treated animals but, in contrast, CO-releasing CORM-2 reduced HO1 mRNA and protein expression at the ulcer margin. Moreover, treatment with CORM-2 and haemin but not ZnPP decreased Nrf2 protein expression, which was increased in the vehicle-treated control ulcer group (not treated with CORM-2). It has been previously reported that HO1 activity is regulated by Nrf2, and CORM-2 increases gastric mucosal expression of HO1 and Nrf2, thus protecting the gastric mucosa from acute injury induced by aspirin (Farombi et al., 2008; Magierowski et al., 2016a) . The results of our study are in keeping with these original observations because HO1 mRNA and Nrf2 protein expressions were found to be elevated at the ulcer margin during ulcer healing. However, in CORM-2 treated animals, this increased expression of HO1 and Nrf2 was inhibited. This could be explained by a negative feedback mechanism evoked by CO released from CORM-2 during the healing of gastric ulcers that might result in the down-regulation of HO1 and Nrf2 protein expression at the ulcer margin.
Interestingly, Hourihan et al. (2013) reported that Nrf2 regulates the expression of the genes of H 2 S-producing enzymes, cystathionine-γ-lyase and cystathionine-β-synthase in mouse embryonic fibroblasts suggesting that this mechanism is involved in cell protection against death induced by menadione. In another study, the H 2 S donor, S-propargyl-
Figure 7
Expression of mRNA for IL-1β, TNF-α and HIF-1α at the ulcer margin and in healthy gastric mucosa. (A) Expression of mRNA for IL-1β in healthy gastric mucosa (intact) and at the gastric ulcer margin [acetic acid (AA) induced ulcer] after 9 days of i.g. treatment with vehicle or CORM-2 (2.5 mg·kg À1 ·day À1 ). (B) Expression of mRNA for TNF-α in healthy gastric mucosa (intact) and at the gastric ulcer margin (AA ulcer) after 9 days of i.g. treatment with vehicle or CORM-2 (2.5 mg·kg À1 ·day À1 ). (C) Expression of mRNA for HIF-1α in healthy gastric mucosa (intact) and at the gastric ulcer margin (AA ulcer) after 9 days of i.g. treatment with vehicle or CORM-2. Results are expressed as mean ± SEM for n = 5 samples per experimental group. Asterisk (*) indicates significant change as compared with healthy gastric mucosa (intact) (P < 0.05). Significant change as compared with the vehicle-treated animals is indicated by a cross ( + ) (P < 0.05).
cysteine was demonstrated to exert a beneficial action via a mechanism involving the translocation of Nrf2 in an animal model of methionine-and choline-deficient diet-induced fatty liver (Li et al., 2016) . It has been also reported that decosahexaenoic acid decreased LPS-induced nitrite release, up-regulated the expression of iNOS expression and increased HO1 expression in mouse macrophages in a Nrf2-dependent manner (Wang et al., 2010) . Taken together, we conclude that all three gaseous mediators, CO, H 2 S and NO, act by modulating the activity of Nrf2 and regulating HO1 expression. Ulcer healing similarly to wound healing is a complex process that requires tissue auto-repair followed by the rapid epithelialization and restoration of gastric glands and angiogenesis within granulation tissue at the ulcer bed (Tarnawski, 2005) . This process is based on a complex mechanism involving the activity of various molecular pathways, hormones and physiological factors including endogenous PGs, NO, TGF-β, afferent sensory nerves and angiogenic VEGFA production (Tarnawski, 2005; Fornai et al., 2011) . We observed that VEGFA protein expression was markedly increased at the ulcer margin following ulcer healing. However, CORM-2 did not influence VEGFA protein expression suggesting that this CO donor does not interfere with the expression of this angiogenic growth factor during ulcer healing. One of the most important components involved in the mechanism of gastric ulcer healing is EGF and its receptor (Tarnawski, 2005) . The expression of EGFR has been observed in gastric progenitor cells (Nguyen et al., 2007) , while the expression of EGF seems to be lower in healthy gastric mucosa. It has been documented that EGF cell lineages are stimulated after exposure to injurious factors to accelerate mucosal cells growth and tissue renewal (Milani and Calabrò, 2001 ). Phosphorylation of EGFR at Tyr 845 in the kinase domain maintains the enzyme in an active state and provides a binding surface for substrate proteins by the stabilization of the activation loop (Cooper and Howell, 1993; Hubbard et al., 1994) . We observed that phospho-EGFR and EGFR protein expression was increased at the ulcer margin at day 9 as the abovementioned physiologically induced tissue auto-repair and cellular proliferation and regeneration marker (Tarnawski, 2005) . Daily treatment with CORM-2 in our study increased the mRNA expression for EGF at ulcer margin. However, treatment with CORM-2 decreased phospho-EGFR expression and the ratio of phospho-EGFR/ EGFR expression. As demonstrated by Wright et al. (1990) and Wong et al. (2000) , EGFR starts to be expressed shortly after ulcer formation. Re-epithelialization of ulcer niche involves the development of cells called ulcer associated-cell lineage, which initially express only EGFR and then start to express EGF (Wright et al., 1990; Wong et al., 2000; Tarnawski, 2005) . Our data suggest that ulcer healing was accelerated in groups treated daily with the CO donor because this gaseous mediator increased EGF mRNA expression at the ulcer margin and, therefore, no further increase in EGFR expression and its phosphorylation was required. As a result, re-epithelialization of the ulcer niche was more effective and advanced at day 9 after ulcer induction in animals treated with CORM-2. Gastric mucosal hyperplasia is characterized by increased macrophage infiltration and an up-regulated expression of pro-inflammatory IL-1β, TNF-α and COX-2 (Fukui et al., 2006) . Granulocyte and macrophage infiltration is increased at the ulcer margin, and it has been suggested that this could be the major source of increased COX-2 expression that is positively regulated by IL-1β and TNF-α Shigeta et al., 1998; Jackson et al., 2000) . Moreover, the increased infiltration of macrophages followed by an up-regulated NOS expression has been observed during the development of chronic gastritis (Cherdantseva et al., 2014) . We observed that CORM-2 decreased mRNA and protein expression of pro-inflammatory factors such as iNOS, as well as COX-2. Additionally, mRNA expression for proinflammatory IL-1β, TNF-α and the induction of hypoxic HIF-1α were ameliorated in groups treated with the CO donor. Our results correspond with previous studies, which revealed that IL-1β, TNF-α mRNA and HIF-1α mRNA and protein expressions were down-regulated in gastric mucosa pretreated with CORM-2 and compromised by stress, the administration of alendronate or aspirin Magierowski et al., 2016a,b) . Additionally, CORM-2 protected the gastric mucosa against aspirin-induced lesions, downregulating the protein expression of iNOS (Magierowski et al., 2017a) . This indicates that CO releasing CORM-2 activity in ulcer healing involves similar factors and mechanisms to those observed in CO-mediated gastroprotection. Therefore, we conclude that CO-mediated acceleration of gastric ulcer healing involves the potent anti-inflammatory and anti-oxidative properties of this gaseous mediator.
Conclusions
CO released from CORM-2 accelerates gastric ulcer healing, and this effect is accompanied by an increase in gastric microcirculation, observed as an enhanced GBF. Endogenously produced CO mediated by the HO1/Nrf2 pathway is involved in the physiological self-curative process of gastric ulcer healing. At the molecular level, the CO-mediated acceleration of gastric ulcer healing depends on an up-regulation in the expression of EGF and its receptor, but CO does not interfere with the activation of angiogenesis at the ulcer margin. The sGC/NO system, K ATP channel and endogenous PGs seem to be involved in the mechanism of acceleration of ulcer healing mediated by this gaseous molecule. Moreover, the increased bioavailability of CO exerts a local vasodilatory and anti-inflammatory action helping the gastric ulcer to heal. Since the animal model of gastric ulcer utilized in our present study mimics many features of human ulcer healing, our results are considered to be translational in that the therapeutic effect of CO in experimental ulcer healing could be further implemented in clinical pharmacology in the context of the prevention and treatment of human peptic ulcers.
